IAG will Participate in the 8th Systemic Sclerosis World Congress

IAG will Participate in the 8th Systemic Sclerosis World Congress

Meet IAG’s Board at the SSWC

IAG’s team is thrilled to announce our participation in 8th Systemic Sclerosis World Congress (SSWC), in Prague, March 14 – 16, 2024.

As the field of systemic sclerosis continues to advance, the upcoming congress promises to be an greate moment, bringing together experts, researchers, and professionals from around the globe to discuss and share the latest scientific discoveries surrounding systemic sclerosis (SSc) through interactive sessions.

Dr. Olga Kubassova, IAG’s President, and Dr. Francesco Del Galdo, IAG’s Scientific Advisory Board member and Associate Professor, Head of Scleroderma Programme at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, will attend this event and meet with multiple stakeholders of the SSc world to exchange cutting-edge insights, share the latest progress IAG has made in the field, and discuss future collaborations.

IAG’s team will present during the ‘BEST FROM THE JOURNALS’ session highlighting the best papers of 2023.

IAG co-authored paper on Digital Artery Volume Index (DAVIX), which was selected as the best paper by Lancet Rheumatology.

Chairpersons: S Onuora (Nature), A Clarke (Lancet Rheumatology), M Trojanowska (Arthritis & Rheumatology), M Matucci-Cerinic (JSRD)
• Journal Scleroderma Related Disorders
Primary SSc heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. (J Scleroderma Relat Disord. 2022;7:24)
C Bruni et al (Italy)

• Lancet Rheumatology
MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with SSc: a prospective cohort study
F Del Galdo et al (UK)

Link to the paper: https://www.thelancet.com/pdfs/journals/lanrhe/PIIS2665-9913(23)00189-3.pdf

• Arthritis Rheumatology
Identification of a Distinct Monocyte‐Driven Signature in SSc Using Biophysical Phenotyping of Circulating Immune Cells
AE Matei et al (Germany)

• Nature Reviews Rheumatology
State-of-the-art evidence in the treatment of SSc, J Pope et al (Canada)

About Image Analysis Group (IAG)

IAG is a unique partner to life sciences companies developing new treatments and driving the hope of upcoming precision medicine. Leveraging expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, IAG de-risks clinical development and delivers life-saving therapies into the hands of patients much sooner. We provide early drug efficacy assessments, intelligent patient recruitment, and predictive analysis of advanced treatment manifestations, thereby lowering investment risk and accelerating study outcomes.

Acting as a medical imaging contract research organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin